作者: Valéria Szijártó , Luis Miguel Guachalla , Katharina Hartl , Cecília Varga , Pallavi Banerjee
DOI: 10.1016/J.IJMM.2015.12.002
关键词:
摘要: Klebsiella pneumoniae ST258 is a globally disseminated, extremely drug resistant, nosocomial clone with limited treatment options. We show that the vast majority of isolates express modified d-galactan-I lipopolysaccharide O-antigen, termed hereinafter as D-galactan-III. The genetic determinant required for galactan-III synthesis was identified distinct operon adjacent to rfb (wb) locus encoding D-galactan-I synthesis. three genes within encode predicted glycosyltransferases. Testing an isogenic transformant pair revealed expression D-galactan-III, in comparison D-galactan-I, conferred improved survival presence human serum. Eighty-three percent more than 200 draft genome sequences currently available carries corresponding and hence these are antigens. A D-galactan-III specific monoclonal antibody (mAb) shown bind extracted LPS from panel isolates. same mAb confirmed accessibility surface staining irrespective capsular antigens expressed by both clades described previously. Based on data, antigen may represent attractive target active passive immunization approaches against K. ST258.